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Abstract Incubation of glutathione (GSH) depleted mouse 
erythrocytes with the oxidants phenylhydrazine, acrolein, 
divicine and isouramil resulted in the release of free iron and in 
lipid peroxidation and hemolysis. The addition of the flavonoid 
quercetin, which chelates iron and penetrates erythrocytes, 
resulted in remarkable protection against lipid peroxidation 
and hemolysis. The protection seems to be due to intracellular 
chelation of iron, since a semi-stoichiometric ratio between 
released iron and the amount of quercetin necessary to prevent 
lipid peroxidation and hemolysis was found. Incubation of GSH 
depleted human erythrocytes with divicine and isouramil did not 
induce lipid peroxidation and hemolysis in spite of a substantial 
release of iron. However, divicine and isouramil produced 
alterations of membrane proteins, such as spectrin and band 3, 
as well as formation of senescent cell antigen. The addition of 
quercetin prevented these alterations. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
It is well known that iron plays a central role in generating 
harmful oxygen species. Its redox cycling, in fact, promotes 
the Fenton reaction in which 0^ ~ reacts with H2O2 to produce 
the very reactive hydroxyl radical [1^1]. Normally iron is 
transported and kept in specific proteins (transferrin, ferritin, 
heme proteins) which prevent its reaction with reduced oxygen 
species [5]. Thus only when iron is released from these com-
plexes in a free form can it be redox cycling active. A low 
molecular weight iron pool is present in the cell as a transit 
pool [6-8], and it is likely that components of this pool rep-
resent the iron species catalytically active in initiating free 
radical reactions. 
Our previous studies [9-11] have shown that iron is released 
in a free (desferrioxamine (DFO) chelatable) form when 
mouse erythrocytes are incubated with a number of oxidizing 
agents such as phenylhydrazine, divicine, isouramil, acrolein, 
phenylhydroxylamine and others. Iron is released from hemo-
globin [10] and the release is accompanied by methemoglobin 
formation [11]. If the erythrocytes are severely depleted of 
glutathione (GSH) (which occurs directly with acrolein 
[9,10,12] or after a short preincubation with GSH depletors 
such as diethylmaleate (DEM) with the other oxidants 
[11,12]), the release of iron is followed by peroxidation of 
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membrane lipids and hemolysis. It seems therefore that the 
release of iron initiates a chain of reactions leading to lipid 
peroxidation and consequent hemolysis. 
Iron acts from the inside of the cell ; in fact, in experiments 
in which the released iron was chelated at the intracellular 
level (in DFO preloaded mouse erythrocytes) lipid peroxida-
tion and hemolysis were prevented, which did not occur with 
extracellularly added DFO [11]. Moreover, only when DFO 
was present in the intracellular compartment in amounts at 
least equivalent to those of the released iron, lipid peroxida-
tion and hemolysis were prevented [11]. 
As is known [13,14] and has been observed in our experi-
ments [11] DFO penetrates cells in minimal amounts only (it 
cannot penetrate human or calf erythrocytes at all). Therefore, 
further studies were carried out with substances capable of 
penetrating the cell and chelating iron. One of these substan-
ces is the flavonoid quercetin, which can penetrate cells (as we 
have verified in preliminary experiments) and which, like its 
rutinoside rutin, can bind iron [15]. Rutin, on the other hand, 
penetrates cells to a small extent [16,17], probably because of 
its hydrophilicity and consequent negligible solubility in eryth-
rocyte membranes. As phenolic compounds, fiavonoids can 
scavenge free hydroxyl and peroxyl radicals [15,18] and can 
react with Superoxide via a one electron transfer [15]; further-
more, as metal chelating agents, they can extract iron ions and 
hinder radical reactions otherwise set into motion by the met-
al redox cycling [15,19-22]. 
In the present work we have studied the effects of quercetin 
on the oxidative alterations of membrane lipids and proteins 
which are induced by the oxidizing agents mentioned above 
and which appear to be mediated by the release of iron. The 
results show that quercetin affords a remarkable protection 
and suggest that the protection is dependent on the intracel-
lular chelation of the released iron. 
2. Materials and methods 
2.1. Materials 
Desferrioxamine (Desferal, DFO) was kindly supplied by Ciba-
Geigy (Basel, Switzerland). Quercetin was from Roth Gmbh and 
Co. (Karlsruhe, Germany); rutin was from Aldrich Chimica (Milan, 
Italy); the other fiavonoids used were from Sigma. Divicine (2,6-dia-
mino-4,5-dihydroxypyrimidme) and isouramil (6-amino-2,4,5-trihy-
droxypyrimidine) were prepared from vicine and convicine respec-
tively, as previously reported [11]. [125I]Protein A (specific activity 
9.01 uCi/ug) was from NEN (Radiochemicals). The solvents used 
for HPLC were of HPLC grade. All other chemicals were of analytical 
grade. 
2.2. Erythrocyte incubation 
In the experiments in which mouse erythrocytes were used, male 
Swiss albino mice (Nossan, Correzzana, Milan, Italy) weighing 25-35 
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g and maintained on a pellet diet (Nossan) were used. Blood was 
withdrawn from the abdominal aorta under ether anesthesia and hep-
arinized. After centrifugation, the plasma and buffy coat were re-
moved. The erythrocytes were washed three times with 0.123 M 
NaCl, 28 mM sodium phosphate/potassium phosphate buffer, pH 
7.4, and resuspended in the same buffer as a 50% (v/v) suspension. 
Iron contamination was removed from the buffer as previously de-
scribed [9]. The hemoglobin concentration, measured as in [23] and 
expressed per heme, was 7100 ±280 nmol/ml. In the experiments in 
which erythrocytes were depleted of GSH, the cells were preincubated 
with 1.5 mM DEM for 15 min at 37°C. DEM was dissolved in a small 
volume of dimethyl sulfoxide (DMSO); DMSO alone had no effect on 
the parameters examined. After preincubation the cells were sedi-
mented, washed, resuspended as above, and used for the subsequent 
incubation. Phenylhydrazine, divicine and isouramil were added at a 
concentration of 1 mM; acrolein was added at a 6 mM concentration 
[9,10]. Quercetin was added at the indicated concentrations. The in-
cubation was carried out aerobically at 37°C. At the end of the in-
cubation, samples were withdrawn for the determination of 'free' iron 
(DFO chelatable), methemoglobin [24], GSH [25], malonaldehyde 
(MDA) [26] and hemolysis [11]. Additional samples were withdrawn 
for the electrophoretic analysis of ghost proteins. 'Free' iron was 
determined as a DFO-iron complex (ferrioxamine) as previously re-
ported [9,10]. 
In the experiments in which human erythrocytes were incubated 
with divicine and isouramil, erythrocytes were prepared from hepa-
rinized blood of volunteers as above. The cells were washed and 
resuspended in the NaCl-sodium phosphate/potassium phosphate 
buffer mentioned above, as a 50% (v/v) suspension. The cells were 
preincubated with 100 |xM quercetin for 15 min at 37°C and subse-
quently with 1 mM 7V-ethylmaleimide (NEM) for an additional 
15 min, in order to obtain GSH depletion. When quercetin was not 
used preincubation was in the only buffer. The cells were then recov-
ered, washed and resuspended as above. The incubation was carried 
out aerobically for 24 and 48 h, in the presence of antibiotics (20 units 
penicillin and 20 ug streptomycin/ml of buffer). Both divicine (0.5 mM) 
and isouramil (0.5 mM) were added to the experimental sample. De-
terminations of 'free' iron, methemoglobin, GSH, MDA and hemol-
ysis were performed as above. Electrophoretic analysis of ghost pro-
teins was also performed. 
In the experiments concerned with the binding of autologous IgG 
to human erythrocytes, the erythrocytes were preincubated and incu-
bated with divicine and isouramil as above. The incubation period 
was 3 h. 
2.3. Experiments carried out in an attempt to extract the quercetin-iron 
complex from the erythrocytes incubated with phenylhydrazine 
Attempts were made to separate quercetin from its complex with 
iron by HPLC, using a Ci8 reverse phase column and phosphate 
buffer (25 mM, pH 7.2) plus acetonitrile (40-60%) as eluent. Different 
eluents were also used but we failed to separate the two substances 
(standard solutions) in any instance. 
In order to prove the intracellular formation of the quercetin-iron 
complex, GSH depleted mouse erythrocytes were incubated with 
phenylhydrazine (1 mM) as above in the presence of 50 u,M quercetin. 
The cells were then lysed by freezing and thawing and the ghosts 
removed by centrifugation. The ghost-free lysate was extracted with 
ethyl acetate. As evidenced by an equally extracted standard of quer-
cetin-iron complex in buffer (pH 7.4), this procedure failed to extract 
the complex, although the uncomplexed (free) quercetin was extracted 
and found to be, when referred to packed cells, 19.5 ±4.6 u.M. Other 
extractions with different solvents equally failed to extract the com-
plex, likely because of its increased hydrophilicity compared to free 
quercetin. In order to have an indirect measurement of the complex, 
the erythrocyte lysate was brought to strongly acid pH (pH 3), to 
produce the dissociation of the complex (as evidenced by the spectro-
photometric change of a standard solution) and to measure free quer-
cetin after extraction with ethyl acetate. However, the latter proce-
dure, under these experimental conditions, resulted in the extraction 
of both free quercetin and hemoglobin products, which made any 
spectrophotometric measurement impossible. To remove these prod-
ucts, the concentrated ethyl acetate extract was applied to a silicic acid 
column (0.8x0.5 cm) and eluted with 3 ml of ethyl acetate. The 
hemoglobin products remained on the top of the column and the 
hemoglobin-free eluent was recovered. Free quercetin was measured 
spectrophotometrically using a standard quercetin-iron complex in 
buffer (pH 7.4), equally acidified (pH 3), extracted and applied to a 
silicic acid column. The recovery of quercetin as measured in this 
standard was low (nearly 40%), likely because quercetin is difficult 
to elute from silicic acid. When calculated on the basis of this recov-
ery, the amount of quercetin present in the erythrocyte lysate and 
referred to packed cells was 80.0 uM. 
2.4. Electrophoretic analysis of ghost proteins 
Erythrocyte ghosts were prepared according to Dodge [27], resus-
pended in 7.5 mM sodium phosphate buffer, pH 7.4, and the protein 
concentration was determined [28], The electrophoretic analysis was 
performed on acrylamide gel (SDS-PAGE) according to Laemmli [29]. 
Molecular weight markers (BDH) were used. 
2.5. Autologous IgG binding to erythrocytes 
IgG was prepared from the serum of the erythrocyte donors by 
precipitation in 40% ammonium sulfate according to Good et al. 
[30]. After dialysis, IgG in 50 mM NaCl/10 mM sodium phosphate, 
pH 7.35, was partially purified on a DEAE column and equilibrated 
with the same buffer, as reported by Levy et al. [31]. The recovered 
IgG was measured spectrophotometrically at 280 nm, using E1%=14.0 
and adjusted at a concentration of 2 mg/ml. 
The binding of autologous IgG to erythrocytes was determined with 
the use of protein A labelled with 125I, according to the procedure 
reported in [32] with minor modifications. 
3. Results 
Fig. 1A shows that the addition of increasing amounts (5, 
10, 25 uM) of FeS04 to quercetin (50 uM) in sodium phos-
phate buffer, pH 7.4, results in a progressive shift of the ab-
sorption maximum from 377 to 420^125 nm. Further addition 
of FeS04 does not modify the 420-425 peak. This suggests 
that at an iron ion concentration half that of quercetin a 
complex is formed in which the molar ratio quercetin:iron is 
2:1. The addition of DFO (50 irM) to the complex (Fig. IB) 
extracts iron from the iron-quercetin complex, as shown by 
the restoration of the quercetin spectrum. 
Similar results were obtained using the other flavonoid 
kaempferol, which therefore seems able to chelate iron. On 
the other hand, other flavonoids such as catechin, hesperitin, 
quercetin (50/ÄJ 
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Fig. 1. A: Absorption spectra of quercetin before (a) and after 
(b,c,d,e) the addition of increasing concentrations of iron sulfate. B : 
Absorption spectra of iron-quercetin complex before (a) and after 
(b) DFO addition. 
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Fig. 2. Structure of quercetin and some related flavonoids. 
lapachol and lawsone did not show similar spectral changes 
upon the addition of FeS04. From these data it could be 
deduced that both the hydroxyl (in C3) and the carbonyl (in 
C4) group of the C ring (see Fig. 2) are necessary to bind iron 
in a stoichiometric ratio of 2:1, at least in the flavonoids 
considered. 
In order to confirm the ability of quercetin to penetrate 
mouse erythrocytes, we incubated 1 ml of packed cells with 
1 ml of 100 uM quercetin in sodium phosphate buffer for 1 h. 
The cells were then removed by centrifugation and the absorp-
tion spectrum (375-380 nm) of the clear supernatant was re-
corded. The absorption was much less than half of that of the 
initial quercetin solution. On the other hand, when rutin was 
used in the same test, all the absorption of the initial rutin 
solution was recovered in the supernatant. Further indications 
of the ability of quercetin to penetrate erythrocytes came from 
the experiments in which the fluorescence of quercetin (several 
flavonoids are fluorescent substances) was recovered in eryth-
rocyte ghosts. To this end the ghosts from 1 ml of packed cells 
were incubated (1 h) with 2 ml of sodium phosphate buffer 
containing 50 uM quercetin. After centrifugation, the ghosts 
and the supernatant were recovered. The ghosts were resus-
pended with 2 ml of the buffer and 2 ml of DMSO and 
examined by spectrofluorophotometry (Exmax, 448 nm; 
Emmax 540 nm). About 90% of the fluorescence of the initial 
quercetin solution was recovered in the ghosts, whereas about 
10% of the fluorescence was recovered in the supernatant to 
which 2 ml of DMSO had been added. These preliminary 
experiments indicated therefore, in agreement with previous 
reports [16,17], that quercetin, unlike rutin, is associated 
with erythrocytes to a great extent. 
In order to investigate the intracellular distribution of quer-
cetin, erythrocytes (50% suspension in buffer) were incubated 
(1 h) in the presence of 50 uM quercetin. After centrifugation 
the clear supernatant was extracted with ethyl acetate. The 
amount of quercetin was measured spectrophotometrically 
with the use of a standard quercetin solution in ethyl acetate 
and found to be 3.7 ± 0.2 u.M. The erythrocytes were then 
lysed (freezing-thawing) and, after sedimentation of the 
ghosts, the ghost-free lysate was extracted with ethyl acetate. 
The amount of quercetin was measured spectrophotometri-
cally in the extract and found to be, when referred to packed 
cells, 74.2 ±2.3 u.M. This indicates that the major part of 
quercetin was in the erythrocyte cytosol. 
In view of the capacity to chelate iron and to penetrate 
cells, quercetin was tested for its ability to prevent the effects 
induced by the oxidizing agents mentioned above (see Section 
1) and likely related to the release of iron into the erythro-
cytes. Table 1 shows that incubation of native mouse eryth-
rocytes with phenylhydrazine induces iron release and meth-
emoglobin formation, but not lipid peroxidation or hemolysis, 
Table 1 
Release of iron (DFO chelatable iron), methemoglobin (Met-Hb) formation, GSH decrease, lipid peroxidation (MDA formation) and hemolysis 
in mouse erythrocytes incubated with phenylhydrazine (Phz) or preincubated with diethylmaleate (DEM) and then incubated with phenylhydra-
zine in the presence or the absence of quercetin 
Control 
Phz 
DEM+Phz 
DEM+Phz+Quercetin 
DEM+Phz+Quercetin 
(15 UM) 
(50 uM) 
Incubation time 
(min) 
0 
60 
60 
60 
60 
60 
'Free iron' 
(nmol/ml) 
1.6 ±0.2 
2.010.4 
19.3±3.1 
24.411.8 
23.912.6 
18.312.5 
Met-Hb 
(nmol/ml) 
103118 
99112 
548124 
10941272 
8191106 
6911155 
GSH 
(nmol/ml) 
876166 
829193 
642146 
236147 
152134 
192145 
MDA 
(nmol/ml) 
-
2.010.6 
2.310.5 
86.714.2 
25.215.4 
0 
Hemolysis 
(%) 
4.410.8 
5.110.9 
6.610.5 
89.212.0 
18.711.4 
5.810.7 
Phz was added to erythrocytes at 1 mM concentration. When DEM pretreated cells were used, the erythrocytes were preincubated with 1.5 mM 
DEM for 15 min, recovered by centrifugation and then incubated with Phz. DEM pretreatment followed by incubation without phenylhydrazine 
did not result in any iron release, lipid peroxidation and hemolysis. Results are the means 1 S.E.M. of three to six experiments. Met-Hb is expressed 
Table 2 
Release of iron (DFO chelatable iron), methemoglobin (Met-Hb) formation, GSH decrease, lipid peroxidation (MDA formation) and hemolysis 
in mouse erythrocytes incubated with acrolein in the presence or the absence of quercetin 
Control 
Acrolein 
Acrolein+Quercetin (5 uM) 
Acrolein+Quercetin (15 uM) 
Acrolein+Quercetin (25 uM) 
Incubation time 
(min) 
0 
90 
90 
90 
90 
90 
'Free iron' 
(nmol/ml) 
2.110.3 
2.710.3 
11.311.0 
6.511.4 
10.911.6 
7.011.2 
Met-Hb 
(nmol/ml) 
74 + 7 
9616 
1295 + 316 
13391482 
1383a 
819a 
GSH 
(nmol/ml) 
921172 
893157 
73111 
10110.3 
150138 
62118 
MDA 
(nmol/ml) 
-
2.310.7 
43.5 + 2.0 
39.913.7 
19.2 + 3.5 
4.711.7 
Hemolysis 
(%) 
4.110.7 
4.810.5 
93.412.1 
63.3114.6 
12.213.2 
8.410.7 
Acrolein was added at 6 mM concentration. Results are the means ± S.E.M. of three to six experiments. Met-Hb is expressed per heme. 
aMean of two experiments. 
126 M. Ferrali et al.lFEBS Letters 416 (1997) 123-129 
Table 3 
Methemoglobin (Met-Hb) formation, lipid peroxidation (MDA formation) and hemolysis in mouse erythrocytes preincubated with diethylma-
leate (DEM) and then incubated with phenylhydrazine (Phz) in the presence or the absence of kaempferol 
Control 
DEM+Phz 
DEM+Phz+Kaempferol (100 liM) 
Phz was added to erythrocytes at 1 mM concentration. Preincubation with DEM was performed as reported in Table 1. Results are the means of 
two experiments. Met-Hb is expressed per heme. The GSH level in native erythrocytes and in erythrocytes preincubated with DEM was 1058 and 
536 nmol/ml, respectively. 
Incubation time 
0 
60 
60 
60 
Met-Hb (nmol/ml) 
102 
119 
512 
307 
MDA (nmol/ml) 
-
1.9 
72.2 
0.1 
Hemolysis (%) 
2.3 
2.9 
89.0 
3.5 
whereas with erythrocytes previously depleted of GSH (by a 
short preincubation with DEM) iron release and methemoglo-
bin formation are accompanied by lipid peroxidation and he-
molysis (Table 1). This confirms our previous results [11]. The 
addition of quercetin in an amount (15 ¡J.M) lower than that 
of the released iron (23.9 |xM), even if it considerably de-
creases lipid peroxidation and hemolysis, does not suppress 
them (Table 1). On the other hand, the addition of quercetin 
in an amount (50 uM) higher than that of the released iron 
completely suppresses lipid peroxidation and hemolysis (Table 
1). As stated above, the molar ratio of quercetin:iron is 2:1 in 
the complex and therefore 50 \iM quercetin is apparently able 
to chelate all the iron (18.3 uM) released in this experiment. 
Indeed, the actual amounts of both free iron and quercetin 
inside the erythrocytes should be considered roughly double 
of those (18.3 and 50 uM, respectively) reported in Table 1, 
since, on the one hand, iron release was determined in the 
lysate from 1 ml of packed cells plus 1 ml of buffer (see 
Section 2), and, on the other hand, most quercetin added to 
the incubation mixture enters the erythrocytes. 
The importance of the ratio between the amount of released 
iron and the amount of added quercetin for the prevention of 
lipid peroxidation and hemolysis is also shown by the experi-
ments carried out with acrolein (Table 2). This aldehyde in-
duces iron release in the erythrocytes [9,10,12], although to a 
lower extent than the other oxidants do. In addition it pro-
duces GSH depletion by directly binding GSH [33-35]. There-
fore, no previous depletion with DEM is needed for lipid 
peroxidation and hemolysis to occur. When quercetin is added 
at a concentration (5 uM) lower than that theoretically equiv-
alent to the amount (6.5 uM) of the released iron, lipid per-
oxidation and hemolysis still occur to a great extent (Table 2). 
When, on the other hand, quercetin is added in a higher 
amount (15 |J.M), but still slightly lower than that theoretically 
necessary to chelate all the released iron (10.9 uM), lipid per-
oxidation and hemolysis are markedly decreased but not com-
pletely suppressed. Finally, when quercetin is added in an 
amount (25 ¡J.M) definitely higher than that of the released 
iron (7 |iM), lipid peroxidation and hemolysis are completely 
prevented (Table 2). 
Further support for the hypothesis that the protective effect 
of quercetin depends on the chelation of the released iron is 
offered by the comparison of the data obtained with phenyl-
hydrazine and with acrolein. The amount of iron released by 
phenylhydrazine is higher than that released by acrolein. Ac-
cordingly, the amount of quercetin necessary to completely 
prevent lipid peroxidation and hemolysis with phenylhydra-
zine is higher (50 uM) than that (25 uM) necessary with acro-
lein. Furthermore, the data obtained with acrolein at 60 min 
of incubation (not reported in Table 2) show that with 15 |J,M 
quercetin lipid peroxidation and hemolysis are completely pre-
vented (MDA: 5.2±1.6 nmol/ml; hemolysis: 7.6±1.4%), 
while with phenylhydrazine the same amount of quercetin 
only decreases the two phenomena (see Table 1). Finally a 
remarkable protective effect on both lipid peroxidation and 
hemolysis induced by phenylhydrazine was also observed (Ta-
ble 3) when using kaempferol, which seems able to chelate 
iron like quercetin. In contrast, no protection was seen with 
hesperitin, which like quercetin and kaempferol enters the cell, 
but seemingly does not chelate iron. 
As stated in Section 2.3, in experiments in which GSH-
depleted mouse erythrocytes were incubated with phenylhy-
drazine in the presence of 50 uJVl quercetin, the attempt to 
measure indirectly the quercetin-iron complex after dissocia-
tion of the complex and measurement of free quercetin re-
sulted in a calculated value of total quercetin of 80 \iM (re-
ferred to packed cells). If one considers that the amount of 
iron released in these conditions is 36.6 uM (referred to 
packed cells; see Table 1) an amount of 73.2 uM quercetin 
can be assumed to be involved in the complex. The amount of 
quercetin apparently remaining free after the incubation is 
19.5 ±4.6 uM (see Section 2.3). Therefore the amount of total 
Table 4 
Release of iron (DFO chelatable iron), methemoglobin (Met-Hb) formation, GSH decrease, lipid peroxidation (MDA formation) and hemolysis 
in mouse erythrocytes incubated with diethylmaleate (DEM) and then incubated with divicine or isouramil in the presence or the absence of 
quercetin 
Control 
DEM+Divicine 
DEM+Divicine+Quercetin (100 uM) 
DEM+Isouramil 
DEM+Isouramil+Quercetin (100 uM) 
Incubation time 
(min) 
0 
60 
60 
60 
60 
60 
'Free iron' 
(nmol/ml) 
2.0 ±0.2 
2.410.3 
24.1 ±2.4 
23.015.4 
25.811.7 
16.311.8 
Met-Hb 
(nmol/ml) 
9418 
119117 
8871151 
25812 
10161248 
162123 
GSH 
(nmol/ml) 
8621121 
-
131117 
210126 
198112 
199134 
MDA 
(nmol/ml) 
-
2.010.4 
76.714.0 
1.611.3 
86.215.1 
1.210.7 
Hemolysis 
(%) 
3.110.5 
4.910.3 
88.614.4 
6.711.6 
81.512.7 
5.211.0 
Divicine and isouramil were added at 1 mM concentrations. Preincubation with DEM was performed as reported in Table 1. Results are the 
means 1 S.E.M. of three experiments. Met-Hb is expressed per heme. 
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Fig. 3. Polyacrylamide gel electrophoresis of ghosts of GSH de-
pleted mouse erythrocytes incubated with divicine (1 mM) or isoura-
mil (1 mM) for 90 min, in the presence or the absence of quercetin 
(100 uM). Lanes: A, molecular weight markers (kDa); B, control, 0 
time; C, control, incubated for 90 min; D, incubated with divicine; 
E, incubated with isouramil; F, incubated with divicine and querce-
tin; G, incubated with isouramil and quercetin. Ten percent poly-
acrylamide gel was used. 
quercetin calculated in the erythrocytes (80 uM) almost com-
pletely accounts for the sum of free quercetin (19.5 uM) plus 
the quercetin-iron complex (73.2 uM). Thus, according to 
these estimations, quercetin seems to have bound intracellu-
larly the released iron. 
The protective effect of quercetin was also seen with the 
pyrimidine aglycones, divicine and isouramil, derived from 
vicine and convicine respectively, the potentially toxic gluco-
sides contained in fava beans {Vicia f aba). Again in erythro-
cytes previously depleted of GSH divicine and isouramil in-
duced, together with iron release and methemoglobin 
formation, lipid peroxidation and hemolysis (Table 4). Again 
quercetin (100 u\M) was able to prevent lipid peroxidation and 
hemolysis (Table 4). 
The electrophoretic analysis of the membrane proteins of 
the same GSH depleted erythrocytes incubated for 90 min 
with divicine and isouramil showed a remarkable decrease in 
a and ß spectrin and in band 3 (Fig. 3). Also bands 4.1, 4.5, 
and 5 were markedly decreased. The addition of quercetin 
(100 uM) completely prevented all these membrane protein 
alterations, suggesting that they are related, at least in part, 
to the release of iron. 
With human erythrocytes divicine and isouramil did not 
induce lipid peroxidation and hemolysis even when the cells 
were depleted of GSH. In these experiments NEM was used 
as GSH depleting agent, since DEM was found to induce very 
Fig. 4. Polyacrylamide gel electrophoresis of ghosts of GSH de-
pleted human erythrocytes preincubated in the presence or the ab-
sence of quercetin (100 uM) and then incubated with divicine (0.5 
mM) and isouramil (0.5 mM) for 48 h, as reported in Table 5. 
Lanes: A, control incubated for 48 h; B, preincubated with querce-
tin and incubated with divicine and isouramil; C, preincubated 
without quercetin and incubated with divicine and isouramil; D, 
molecular weight markers (kDa). Fifteen percent polyacrylamide gel 
was used. 
low GSH depletion in human erythrocytes. However, even 
after preincubation with NEM the GSH level was decreased 
by only 34% which is much less than the decrease (70-85%) 
obtained with DEM in mouse erythrocytes. Therefore the in-
cubation with divicine and isouramil was prolonged to 24 and 
48 h. Even at the latter time lipid peroxidation and hemolysis 
did not occur (Table 5), even if a substantial release of iron 
and a more severe GSH depletion (—70%) were seen. In spite 
of the inability to induce lipid peroxidation, divicine and iso-
uramil produced, during the same incubation time (48 h), 
alterations of membrane proteins (Fig. 4) similar to those 
seen in mouse erythrocytes (see Fig. 3) and consisting in an 
almost complete disappearance of a and ß spectrin and band 
3, in a marked decrease of bands 4.1 and 4.2 and in the 
appearance of new bands around 66 kDa. Preincubation 
with quercetin (100 (J,M) completely prevented these mem-
brane protein alterations, suggesting again that they are re-
lated to the release of iron. 
It must be noted that in these experiments substantial iron 
release occurred even in control erythrocytes incubated for 48 
h in the absence of divicine and isouramil (Table 5), which 
confirms our previous results [32] that prolonged aerobic in-
cubation induces the release of iron. This release is not ac-
companied by membrane protein alterations (Fig. 4) probably 
because the GSH level is maintained to a certain extent. 
We have recently suggested [32] the possibility that the re-
lease of iron in a redox active form is related to the generation 
of senescent antigen (the antigen appearing on aged erythro-
Table 5 
Release of iron (DFO chelatable iron), methemoglobin (Met-Hb) formation, GSH decrease and hemolysis in human erythrocytes preincubated 
with quercetin and subsequently with W-ethylmaleimide (NEM), and then incubated with divicine and isouramil 
Incubation time (h) 'Free iron' (nmol/ml) Met-Hb (nmol/ml)|i GSH (nmol/ml) Hemolysis (%) 
No addition 0 
48 
48 
48 
1.0 ±0.2 
15.0±2.1 
21.0±2.7 
20.8 ±3.0 
123± 11 
322 ±31 
1177 ±90 
1240 ±54 
521 ±67 
503 ± 72 
256 ±30 
204 ±54 
2.7 ±0.3 
9.2 ±0.9 
11.7±1.1 
7.5 ±0.9 
Divicine+Isouramil 
Divicine+Isouramil+Quercetin 
The erythrocytes were preincubated with 100 uM quercetin and subsequently with 1 mM NEM. The first preincubation step was in the only buffer 
when quercetin was not used. The cells were recovered by centrifugation and then incubated with 0.5 mM divicine and 0.5 mM isouramil. Results 
are the means ±S.E.M. of three experiments. Met-Hb is given per heme. The GSH level in native (not preincubated) erythrocytes was 885 ± 104 
nmol/ml. Lipid peroxidation (MDA formation) was negligible ( > 2 nmol/ml) in all the experiments. In some experiments severe hemolysis occurred 
at 24 or 48 h in all the samples (including controls, no addition). These experiments were discarded. 
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Table 6 
Binding of autologous IgG to human erythrocytes preincubated with quercetin and subsequently with JV-ethylmaleimide and then incubated 
with divicine and isouramil 
Incubation time (h) GSH (nmol/ml Bound IgG (No. of molecules per cell) 
Control 
Divicine+Isouramil 
Divicine+Isouramil+Quercetin 
323 ±7 
238 ±19 
213±38 
224 ±65 
13.9 ±2.3 
17.5 ±6.1 
33.2 ±9.4 
17.1 ±2.0 
The erythrocytes were preincubated and incubated as reported in Table 5, with the only difference that the incubation period was 3 h. 
cytes [36]), the link being represented by metal catalyzed ox-
idation of membrane proteins [32]. In fact, under some con-
ditions in which a marked iron release occurs in the erythro-
cytes, senescent cell antigen is also formed. These conditions 
were prolonged (60 h) aerobic incubation (in vitro ageing) and 
incubation with phenylhydrazine [32]. Here we show (Table 6) 
that incubation (3 h) with divicine and isouramil also gives 
rise to the formation of senescent antigen (as measured by the 
binding of autologous IgG). Preincubation with quercetin 
(100 uM) almost completely prevents the autologous IgG 
binding that is the formation of senescent antigen. 
4. Discussion 
The present results clearly show that the flavonoid quercetin 
is able to prevent the oxidative damage induced in the eryth-
rocyte membrane by a number of oxidizing agents, such as 
phenylhydrazine, acrolein, divicine and isouramil; damage to 
membrane lipids (lipid peroxidation and consequent hemoly-
sis) or proteins (severe decrease in spectrin and band 3, and 
senescent cell antigen formation). 
With all these agents iron is released in a free, redox active 
form. The release of iron appears to be responsible for lipid 
peroxidation and consequent hemolysis [11]. Also the mem-
brane protein alterations resulting in the formation of senes-
cent cell antigen appear to be related to the release of iron 
[32]. The results of the present report seem to indicate that the 
protection afforded by quercetin is due to intracellular chela-
tion of iron. This possibility is supported by (i) the semi-stoi-
chiometric ratio between the amount of released iron and the 
amount of quercetin necessary to prevent lipid peroxidation 
and hemolysis, as found in the experiments with phenylhydra-
zine and acrolein; (ii) the ability to prevent lipid peroxidation 
and hemolysis of kaempferol which binds iron and the inabil-
ity of hesperitin which does not; (iii) the results of the experi-
ments carried out in an attempt to extract the quercetin-iron 
complex from the erythrocytes incubated with phenylhydra-
zine. Unfortunately, the latter results proved the formation of 
the complex only indirectly, while in previous studies [11] with 
DFO preloaded erythrocytes (see Section 1) it was possible to 
extract the ferrioxamine complex. 
The possibility must also be considered that the effect of 
quercetin is due to its antioxidant activity (which has been 
extensively documented, see [37^-1]), independently of metal 
chelation. Probably both activities are involved in the protec-
tive effect and it is difficult to distinguish the respective roles 
played. We think, however, that, in our model system, the 
iron chelating capacity of quercetin is important, since in pre-
liminary experiments we have observed that in GSH depleted 
mouse erythrocytes vitamin E (which does not chelate iron) is 
able to prevent the phenylhydrazine induced lipid peroxida-
tion independently of the amount of released iron. In the 
present study the use of quercetin was aimed at blocking 
the redox cycling of free iron, which can act on both mem-
brane lipids and proteins. Other iron chelators able to enter 
erythrocytes are currently being studied in our laboratory with 
the aim of preventing the damaging effect of iron release. For 
instance, a remarkably high free iron level and DNA damage 
have been observed in the hepatocytes [42] in phenylhydrazine 
induced iron overload. Furthermore, since iron is released in 
the erythrocytes during blood storage [32], chelation of iron at 
the intracellular level could represent a means to delay the 
formation of senescent antigen and to prolong the storage 
time of blood in blood stores. 
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